Gsa Capital Partners LLP Immatics N.V. Transaction History

Gsa Capital Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.31 - $13.06 $40,842 - $161,147	12,339 New	12,339 $123,000
Q2 2022 Aug 09, 2022	SELL	$6.0 - $9.37 $80,058 - $125,023	-13,343 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$6.64 - $12.85 $42,987 - $83,190	-6,474 Reduced 32.67%	13,343 $107,000
Q4 2021 Feb 14, 2022	BUY	$10.81 - $14.38 $214,221 - $284,968	19,817 New	19,817 $266,000

101

75.8M

238K

727K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $623M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.